01IDENTIFICATION
A child with established myopia or material risk factors enters a structured assessment pathway. Passive “watch and wait” is not the default management model.
02BIOMETRY
The baseline is built primarily from cycloplegic refraction, axial-length measurement and documentation of ocular structures. When RLRL is considered, baseline macular OCT forms part of safety monitoring.
03MEDICAL ELIGIBILITY
The physician analyses the data, examines the patient, assesses the fundus and excludes contraindications. Only then is the appropriate intervention selected.
04PRESCRIPTION
The treating physician defines how therapy is delivered for the individual patient. The decision covers initiation, follow-up schedule and subsequent conditions for continuation, modification or completion.
05TECHNICAL ACTIVATION
The technical layer covers device supply and activation, application setup and service support. It is not the layer in which clinical decisions are made.
06CAREGIVER TRAINING
The caregiver is trained to deliver the prescribed protocol and respond appropriately to symptoms. Clinical concerns return to the treatment centre and supervising physician, not the technical layer.
07DELIVERY
Therapy is delivered according to the physician's prescription and the device parameters defined by the manufacturer. Emission parameters are not independently modified by pathway participants.
08MONITORING
Efficacy and safety monitoring uses axial length, spherical equivalent refraction, visual acuity and — where required — OCT. Results are interpreted by the physician.
09CHANGE / TAPERING / COMPLETION
Continuation, escalation, gradual tapering, de-escalation or treatment completion follows renewed clinical assessment. It is not an automatic decision made by the device, application or distributor.
